These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 17051134)

  • 1. Ranibizumab (Lucentis) for macular degeneration.
    Med Lett Drugs Ther; 2006 Oct; 48(1246):85-6. PubMed ID: 17051134
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ranibizumab (Lucentis) in the treatment of age-related macular degeneration].
    Studnicka J
    Cesk Slov Oftalmol; 2009 May; 65(3):107-11. PubMed ID: 19642358
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration.
    Mojica G; Hariprasad SM; Jager RD; Mieler WF
    Br J Ophthalmol; 2008 Apr; 92(4):584. PubMed ID: 18369083
    [No Abstract]   [Full Text] [Related]  

  • 7. [The results of wet AMD treatment by intravitreal injections--preliminary report].
    Okruszko A; Borucka AI; Ulińska M; Szaflik J
    Klin Oczna; 2007; 109(10-12):389-93. PubMed ID: 18488380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Angiogenesis inhibitors for vision loss. Ranibizumab for macular degeneration].
    Mohr-Andrä M; Mohr K
    Pharm Unserer Zeit; 2007; 36(6):437-40. PubMed ID: 17957687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranibizumab according to need: a treatment for age-related macular degeneration.
    Spaide R
    Am J Ophthalmol; 2007 Apr; 143(4):679-80. PubMed ID: 17386275
    [No Abstract]   [Full Text] [Related]  

  • 10. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.
    Parravano M; Oddone F; Tedeschi M; Schiano Lomoriello D; Chiaravalloti A; Ripandelli G; Varano M
    Retina; 2009 Mar; 29(3):329-34. PubMed ID: 19092732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranibizumab: new drug. Macular degeneration: second-line use due to risks.
    Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inadvertent injection of intravitreal air during intravitreal Lucentis injection for wet age-related macular degeneration: an undescribed complication.
    Somner JE; Mansfield D
    Eye (Lond); 2009 Aug; 23(8):1744. PubMed ID: 18836410
    [No Abstract]   [Full Text] [Related]  

  • 13. Ranibizumab treatment of patients with ocular diseases.
    Dugel PU
    Int Ophthalmol Clin; 2006; 46(4):131-40. PubMed ID: 17060799
    [No Abstract]   [Full Text] [Related]  

  • 14. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
    Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
    Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
    Regillo CD; Brown DM; Abraham P; Yue H; Ianchulev T; Schneider S; Shams N
    Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ranibizumab--effective, but expensive in macular degeneration].
    Frennesson C
    Lakartidningen; 2008 Aug 6-19; 105(32-33):2161. PubMed ID: 18780688
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.
    Uparkar M; Bhende M
    Retina; 2009; 29(10):1549; author reply 1549-50. PubMed ID: 19898197
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.